BR112012022223A8 - Formulação de proteína concentrada, uso e método de preparação da mesma - Google Patents

Formulação de proteína concentrada, uso e método de preparação da mesma

Info

Publication number
BR112012022223A8
BR112012022223A8 BR112012022223A BR112012022223A BR112012022223A8 BR 112012022223 A8 BR112012022223 A8 BR 112012022223A8 BR 112012022223 A BR112012022223 A BR 112012022223A BR 112012022223 A BR112012022223 A BR 112012022223A BR 112012022223 A8 BR112012022223 A8 BR 112012022223A8
Authority
BR
Brazil
Prior art keywords
preparation
formulations
concentrated protein
protein formulation
protein drug
Prior art date
Application number
BR112012022223A
Other languages
English (en)
Other versions
BR112012022223A2 (pt
BR112012022223B1 (pt
Inventor
T Chen Tracy
Original Assignee
Progenics Pharm Inc
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc, Cytodyn Inc filed Critical Progenics Pharm Inc
Publication of BR112012022223A2 publication Critical patent/BR112012022223A2/pt
Publication of BR112012022223A8 publication Critical patent/BR112012022223A8/pt
Publication of BR112012022223B1 publication Critical patent/BR112012022223B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

FORMULAÇÕES DE PROTEÍNA CONCENTRADA E SEU MÉTODO DE PREPARAÇÃO. A presente invenção refere-se a viscosidade, hipotônica formulações contendo um ou mais proteínas, por exemplo, anticorpos, a altas concentrações, usos das formulações e artigos de manufatura. Em particular, as formulações são úteis e benéficas para a administração ou distribuição subcutânea de uma alta concentração de um fármaco de proteína, tal como um anticorpo, a um indivíduo que está sofrendo com uma doença ou condição que e tratável por um fármaco de proteína.
BR112012022223-6A 2010-03-01 2011-03-01 Formulação de proteína concentrada, uso e método de preparação da mesma BR112012022223B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33919110P 2010-03-01 2010-03-01
US61/339,191 2010-03-01
PCT/US2011/026647 WO2011109365A2 (en) 2010-03-01 2011-03-01 Concentrated protein formulations and uses thereof

Publications (3)

Publication Number Publication Date
BR112012022223A2 BR112012022223A2 (pt) 2016-07-05
BR112012022223A8 true BR112012022223A8 (pt) 2017-12-05
BR112012022223B1 BR112012022223B1 (pt) 2022-08-09

Family

ID=44542798

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022223-6A BR112012022223B1 (pt) 2010-03-01 2011-03-01 Formulação de proteína concentrada, uso e método de preparação da mesma

Country Status (16)

Country Link
US (2) US9956165B2 (pt)
EP (1) EP2542221A4 (pt)
JP (2) JP5937523B2 (pt)
KR (1) KR101853981B1 (pt)
CN (2) CN102946861B (pt)
AU (2) AU2011223805B2 (pt)
BR (1) BR112012022223B1 (pt)
CA (1) CA2794929C (pt)
HK (1) HK1223835A1 (pt)
IL (1) IL221748B (pt)
MX (1) MX347504B (pt)
NZ (1) NZ602685A (pt)
RU (1) RU2626512C2 (pt)
SG (1) SG184355A1 (pt)
WO (1) WO2011109365A2 (pt)
ZA (1) ZA201207331B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
CA3017116A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
MX352823B (es) * 2011-10-28 2017-12-04 Integritybio Inc Formulaciones de proteinas que contienen aminoacidos.
US10316095B2 (en) * 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
ES2908474T3 (es) 2012-05-03 2022-04-29 Boehringer Ingelheim Int Anticuerpos anti-IL-23p19
PE20191815A1 (es) 2012-09-07 2019-12-27 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
KR20150056846A (ko) * 2012-09-20 2015-05-27 모르포시스 아게 류마티스 관절염에 대한 치료
EP3043774B1 (en) 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EP2946765B1 (en) 2014-05-23 2016-08-31 Ares Trading S.A. Liquid pharmaceutical composition
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
AU2015305401A1 (en) 2014-08-20 2017-03-02 Cytodyn Inc. HIV antibody therapy as treatment substitute
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2017111228A (ru) * 2014-10-18 2018-11-21 Пфайзер Инк. Композиции антитела против IL-7R
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
MX2017009759A (es) 2015-01-28 2017-10-27 Pfizer Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
LT3256154T (lt) * 2015-02-09 2020-01-10 UCB Biopharma SRL Farmacinė kompozicija, apimanti antikūną
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
CN113648410A (zh) * 2015-06-23 2021-11-16 西托戴恩股份有限公司 Ccr5受体竞争性抑制剂、其应用和治疗方法
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
TW201726111A (zh) * 2015-09-30 2017-08-01 持田製藥股份有限公司 含高濃度抗體之液體製劑
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
EA202190808A2 (ru) 2015-11-03 2021-12-31 Янссен Байотек, Инк. Составы антител к cd38 для подкожного введения и их применение
SG11201807402PA (en) 2016-03-31 2018-09-27 Vhsquared Ltd Compositions
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
TWI826351B (zh) * 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
CN109562149A (zh) 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
AU2018269656A1 (en) * 2017-05-16 2019-11-07 Octapharma Ag C1-esterase inhibitor preparation
JP2020530004A (ja) * 2017-08-03 2020-10-15 ジャズ ファーマシューティカルズ アイルランド リミテッド 核酸を高濃度で含む製剤
KR102208378B1 (ko) * 2017-08-17 2021-01-28 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
US20190085086A1 (en) 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
WO2019217927A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CN111595658B (zh) * 2020-06-06 2023-11-14 宾傲 一种提取细胞中蛋白的裂解液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
KR100913714B1 (ko) * 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
RU2357751C2 (ru) * 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
KR101080021B1 (ko) * 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
NZ561465A (en) 2002-02-22 2009-04-30 Pdl Biopharma Inc Anti-CCR5 antibody
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
WO2004075913A1 (ja) 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
EA010979B1 (ru) * 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
WO2006007412A2 (en) * 2004-06-16 2006-01-19 Nastech Pharmaceutical Company Inc. Peptide yy formulations having increased stability and resistance to microbial agents
AR057807A1 (es) 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
EP1942868B2 (en) * 2005-11-01 2023-10-04 Wyeth LLC Sodium chloride solution for drug reconstitution or dilution
US7390786B2 (en) * 2005-12-21 2008-06-24 Wyeth Protein formulations with reduced viscosity and uses thereof
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof

Also Published As

Publication number Publication date
BR112012022223A2 (pt) 2016-07-05
AU2016200495B2 (en) 2017-11-09
JP2013521296A (ja) 2013-06-10
CN105521491A (zh) 2016-04-27
EP2542221A2 (en) 2013-01-09
RU2012141655A (ru) 2014-04-10
KR101853981B1 (ko) 2018-05-02
US11571383B2 (en) 2023-02-07
KR20130010898A (ko) 2013-01-29
US20180263898A1 (en) 2018-09-20
JP6229007B2 (ja) 2017-11-08
ZA201207331B (en) 2014-07-30
CA2794929C (en) 2018-06-05
CN102946861B (zh) 2016-01-20
WO2011109365A3 (en) 2012-01-05
AU2016200495A1 (en) 2016-02-18
HK1223835A1 (zh) 2017-08-11
CN102946861A (zh) 2013-02-27
SG184355A1 (en) 2012-11-29
BR112012022223B1 (pt) 2022-08-09
CN105521491B (zh) 2020-03-24
WO2011109365A2 (en) 2011-09-09
JP2016193911A (ja) 2016-11-17
IL221748B (en) 2019-09-26
CA2794929A1 (en) 2011-09-09
US20130216525A1 (en) 2013-08-22
AU2011223805A1 (en) 2012-10-25
NZ602685A (en) 2014-10-31
US9956165B2 (en) 2018-05-01
MX347504B (es) 2017-04-28
AU2011223805B2 (en) 2015-10-29
EP2542221A4 (en) 2013-10-23
RU2626512C2 (ru) 2017-07-28
MX2012010114A (es) 2013-01-29
JP5937523B2 (ja) 2016-06-22

Similar Documents

Publication Publication Date Title
BR112012022223A8 (pt) Formulação de proteína concentrada, uso e método de preparação da mesma
BR112014028600A8 (pt) Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
GT201700096A (es) Formulación estable de proteína en solución que contiene una alta concentración de un anticuerpo anti-vegf
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
BR112014030820A2 (pt) formulação de anticorpos
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
UY35195A (es) Composiciones y metodos para proteinas de accion prolongada
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BR112014021101A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
BR112013000392B8 (pt) Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
BR112012027055A8 (pt) agente estabilizante para proteínas farmacêuticas.
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
BR112014031841A2 (pt) formulação farmacêutica
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
AR091155A1 (es) Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion
BR112014028997A2 (pt) formulações estabilizadas contendo anticorpos anti-dll4
BR112014000721A2 (pt) método de uso de proteínas funcionais ativadas para aprimorar a saúde animal
BR112013001462B8 (pt) Composições
BR112014015605A2 (pt) método de reconstituição para formulações de proteína seca de alta concentração
BR112013025410A2 (pt) tratamento terapêutico

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CYTODYN INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 39/395 (2006.01), A61K 4

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.